Technology
Health
Biotechnology

Prothena

$9.49
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.55 (6.15%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Prothena and other stocks, options, ETFs, and crypto commission-free!

About

Prothena Corporation plc Ordinary Shares, also called Prothena, is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. Read More The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Employees
59
Headquarters
Dun Laoghaire, Dublin
Founded
1969
Market Cap
378.31M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
429.85K
High Today
$9.61
Low Today
$8.98
Open Price
$9.00
Volume
733.72K
52 Week High
$15.91
52 Week Low
$8.63

Collections

Technology
Health
Biotechnology
Medical
Europe (Non-UK)
Europe

News

Yahoo FinanceMay 11

Here’s What Hedge Funds Think About Prothena Corporation plc

How do we determine whether Prothena Corporation plc (NASDAQ:PRTA) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that their consensus long positions have historically outperformed the market when we adjust for known risk factors. Is Prothena Corporation plc (NASDAQ:PRTA) the right pick for your portfolio...

17
Yahoo FinanceMay 7

Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of 13.33% and -7.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

11
Markets InsiderMay 7

Prothena Reports First Quarter 2019 Financial Results and Provides R&D Update

Net cash used in operating and investing activities was $17.6 million in the first quarter; quarter-end cash and restricted cash position of $414.2 million provides funding to advance neuroscience pipeline Initiated cell line development of a lead candidate for preclinical tau program DUBLIN, Ireland, May 07, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported financial results for the first quarter of 2019. In addition, the Company pr...

5

Earnings

-$1.48
-$1.16
-$0.84
-$0.52
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.